We are excited to announce that BioStem Technologies (OTC: BSEM) will be presenting at the Planet MicroCap Las Vegas 2026 Conference, one of the premier events connecting emerging growth companies with the investment community.
hubs.ly/Q04kYh7g0
#MicroCap $BSEM
51
Jun 10
$BSEM BioStem Technologies (OTC: BSEM) will present at Planet MicroCap Las Vegas 2026, highlighting its regenerative medicine portfolio, tissue technologies, and growth strategy tinyurl.com/bsemjun10 The latest news and updates relating to $BSEM are available at the company’s newsroom: tinyurl.com/bsemnewsroom
ALT BioStem Technologies (OTC: BSEM), a regenerative medicine innovator specializing in perinatal tissue allografts, will present at the Planet MicroCap Las Vegas 2026 Conference on June 17. The company develops advanced tissue solutions using proprietary BioRetain®, CryoTek®, and SteriTek® technologies, supported by AATB-accredited quality systems, expanding clinical research, and a growing national commercial presence.
79
Whether you're a clinician, healthcare executive, researcher, distributor, or investor, we invite you to stop by, meet our team, and learn how BioStem is helping redefine advanced acute and chronic wound care. Click for schedule: hubs.ly/Q04kty-D0
$BSEM #woundcare #events
37
Jun 9
Biostem Technologies renova conselho técnico, de olho na Nasdaq
br.advfn.com/jornal/2026/06/…
32
Jun 9
BioStem Technologies Expands Board with Three Appointments as Nasdaq Uplisting Remains a Key Objective (BSEM) investorshub.advfn.com/marke…
78
$BSEM BioStem Technologies (OTC: BSEM) appoints three independent directors with expertise in life sciences, healthcare leadership, and investment management to support growth and governance tinyurl.com/bsemjun9 The latest news and updates relating to $BSEM are available at the company’s newsroom: tinyurl.com/bsemnewsroom
ALT BioStem Technologies (OTC: BSEM) announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, strengthening expertise in life sciences commercialization, healthcare administration, and investment management. The appointments support the company’s growth strategy, governance enhancements, and planned Nasdaq uplisting, while two outgoing directors step down after their service
1
181
Jun 8
โพสต์ X โดย @jsh3pump_
นำเสนออย่างขบขันถึงหุ้นไบโอเทคเกาหลีราคาต่ำในปี 2026 ที่กำลังดำเนินการรวมหุ้น (reverse split) โดยมีคำบรรยายว่า "รวมกันเรายืนหยัด!" เพื่อล้อเลียนกลยุทธ์การเอาตัวรอดจากราคาที่ต่ำและความเสี่ยงจากการถูกถอดออกจากตลาด
ตารางที่แนบมาแสดงรายชื่อบริษัทเจ็ดแห่ง เช่น Humasis (16 เม.ย.: 100→500 วอน), HLB Biostem (28 เม.ย.: 500→2500 วอน), CU Medical, NeoImmuneTech และ Noul (22 ส.ค.) รวมถึงราคา ก่อน/หลัง ผลการดำเนินงานล่าสุด และมูลค่าตลาด
สิ่งนี้สะท้อนให้เห็นถึงแนวโน้มที่เกิดขึ้นจริงในตลาด KOSDAQ ซึ่งบริษัทไบโอหลายแห่งรวมหุ้นเพื่อให้เป็นไปตามกฎการจดทะเบียนท่ามกลางผลการดำเนินงานที่อ่อนแอของภาคส่วน โดยมักจะมีความผันผวนของราคาในระยะสั้นหลังการปรับราคา
1
118
“This milestone reflects our continued focus on protecting the innovation behind our advanced perinatal tissue allograft technologies.”
— Jason Matuszewski, CEO, BioStem Technologies. hubs.ly/Q04hjSQW0
#BioStem #RegenerativeMedicine #WoundCare #Biotech #Innovation $BSEM
2
33
BioStem Technologies reported Q1 2026 financial results, marking a transformational quarter as the Company continues integrating the acquired BioTissue surgical and wound care assets and expanding its hospital-focused commercial strategy.
Link:hubs.ly/Q04gHpVQ0
$BSEM
1
2
3
207
$BSEM 𝐁𝐢𝐨𝐒𝐭𝐞𝐦 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬: 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐃𝐨𝐰𝐧, 𝐍𝐚𝐬𝐝𝐚𝐪 𝐔𝐩𝐥𝐢𝐬𝐭 𝐏𝐮𝐬𝐡 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬
📊 𝐑𝐞𝐬𝐮𝐥t𝐬
• Revenue: $6.1M vs. $16.0M YoY
• Gross profit: $3.8M
• Gross margin: 61% vs. 95% YoY
• Operating expenses: $12.6M vs. $9.9M YoY
• GAAP net loss: $(8.8M) vs. $3.9M net income YoY
• Adjusted EBITDA: $(5.7M) vs. $7.8M YoY
• Cash: $13.7M vs. $29.5M QoQ
⠀
🎯 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞
• FY2026 revenue: $25M–$29M
⠀
📌 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
• Hospital revenue represented 87% of total Q1 sales
• Gross margin pressure tied to Neox and Clarix product mix shift
• Direct sales force expanded to 35 reps following BioTissue asset acquisition
• Company retired ~$5.3M of GMA debt
• Nasdaq uplisting process continues following completion of 2024 and 2025 audits
⠀
💬 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐞𝐧𝐭𝐚𝐫𝐲
“We completed our acquisition of the surgical and wound care assets from BioTissue and repositioned the company as a fully integrated, hospital-focused commercial organization.”
2
308
May 14
$BSEM BioStem Technologies (OTC: BSEM) reports Q1 2026 revenue of $6.1M, hospital-led growth strategy, BioTissue integration progress, and Nasdaq uplisting plans tinyurl.com/bsemmay142026 The latest news and updates relating to $BSEM are available in the company’s newsroom at: tinyurl.com/bsemnewsroom
ALT $BSEM - BioStem Technologies (OTC: BSEM) reported Q1 2026 revenue of $6.1M as it shifts toward a hospital-focused regenerative medicine model after acquiring BioTissue assets. The company expanded its sales force, advanced Nasdaq uplisting plans, retired debt, and expects 2026 revenue of $25M–$29M.
2
247
BioStem is proud to announce our participation in the upcoming ACOG Annual Clinical & Scientific Meeting in Washington, D.C., May 1–3, 2026. Join us starting Friday at ACOG and be part of the conversation shaping the future of women’s health.
#ACOG #WomensHealth $BSEM #OBGyn
3
70
BioSTEM III students are working on gel electrophoresis lab with candy dye. Next step is doing plant DNA.
#nshsindians
4
6
396
We’re excited to announce that BioStem Technologies will be exhibiting at the ASCRS Annual Scientific Meeting in Tampa, FL, May 9–12, 2026! Tampa, FL., May 9–12, 2026, Booth #919 Stop by, meet the team, and discover what sets BioStem apart.
#ASCRS26 $BSEM #woundcare
2
117
BioStem Technologies invites you to join us for an exciting virtual conference focused on Lower Extremity Sports Injuries—where innovation meets performance. Saturday, May 2, 2026, from 8:30 AM – 12:30 PM EST
Reserve your spot: hubs.ly/Q04d2ysG0
#SportsMedicine $BSEM
3
67
Apr 22
WATCHING THIS AGAIN!
(OTC: $BSEM) BioStem Technologies Watching this in 2026 for the $25 target and uplisting potential
✅7 straight profitable quarters
✅$25.50 Zacks target
✅Nasdaq uplisting in focus
BSEM kicked off 2026 with a major acquisition valued at up to $40M, adding Neox® and Clarix® while expanding into hospital based wound care.
With 88.5% gross margins, $10.5M quarterly revenue, and expected added annual revenue from the deal, this is a profitable small cap worth watching.
Communicated Disclaimer
tinyurl.com/CooperBagsDiscla…
4
5
2,435
Apr 22
(OTC: $BSEM) BioStem Technologies Watching this in 2026 for the $25 target and uplisting potential
✅7 straight profitable quarters
✅$25.50 Zacks target
✅Nasdaq uplisting in focus
BSEM kicked off 2026 with a major acquisition valued at up to $40M, adding Neox® and Clarix® while expanding into hospital based wound care.
With 88.5% gross margins, $10.5M quarterly revenue, and expected added annual revenue from the deal, this is a profitable small cap worth watching.
Communicated Disclaimer
tinyurl.com/EquityGenieDiscl…
2
8
13
3,029
Apr 22
🚨 $BSEM THIS SMALL CAP IS QUIETLY PRINTING PROFIT
BSEM isn’t just another biotech story, it’s a profitable, high-margin machine positioning for a breakout year.
Why BioStem deserves your attention:
▫️ Major 2026 acquisition (up to $40M): adds Neox & Clarix
▫️ Expanding aggressively into hospital-based wound care
▫️ 88.5% gross margins (elite tier profitability)
▫️ $10.5M quarterly revenue new revenue streams coming online
▫️ Uplisting potential $25 target in sight
This isn’t speculation… this is a scaling, revenue-generating company still trading like it hasn’t been discovered.
Ask yourself:
What happens when a profitable small cap with nearly 90% margins gets uplisted and finally hits institutional radar?
⚠️ The window to front-run that move doesn’t stay open forever.
Communicated - Disclaimer:
fh.bio/jcoop
7
7,063
Join Us in Austin for an Exclusive Surgical Forum. BioStem Technologies is bringing together leading physicians from across the country for an engaging discussion on advancing surgical outcomes. May 8–9 in Austin, TX. Email: meded@biostemtech.com to attend.
$BSEM #suricalforum
2
65